This prognostic value extends to pan-cancer analysis, where STC2 expression levels were significantly elevated in various cancer types, particularly in advanced stages and lymph node metastasis samples. This evidence concerns the gene STC2 and metastatic malignant neoplasm in the lymph nodes.